Please enable JavaScript to continue using this application.

Compare $ENTA vs $SRZN | Chartloom

Compare

$ENTA vs $SRZN

Enanta Pharmaceuticals Inc · Surrozen Inc

ENTA

Enanta Pharmaceuticals Inc

SRZN

Surrozen Inc

Compare $ENTA vs $SRZN

Comparing Enanta Pharmaceuticals Inc and Surrozen Inc

ENTAEnanta Pharmaceuticals Inc

SRZNSurrozen Inc

ENTAEnanta Pharmaceuticals Inc

Market cap

$364M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

6.51x

Rev growth (TTM)

0.7%

YTD performance

-13.3%

52W performance

10.6%

FCF yield

-10.2%

SRZNSurrozen Inc

Market cap

$345M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

118.58x

Rev growth (TTM)

-8.8%

YTD performance

37.8%

52W performance

111.5%

FCF yield

-10.1%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

ENTA

SRZN

Detailed metrics comparison

ENTA

Enanta Pharmaceuticals Inc

SRZN

Surrozen Inc

Market Cap

ENTA$364M

SRZN$345M

Enterprise Value

ENTA$456M

SRZN$243M

Price

ENTA$12.50

SRZN$29.69

P/E Ratio

ENTAN/A

SRZNN/A

P/S Ratio

ENTA5.57x

SRZN29.95x

EV/Sales

ENTA6.99x

SRZN21.08x

EV/EBITDA

ENTA31.83x

SRZN0.00x

P/B Ratio

ENTA3.73x

SRZN7.31x

P/FCF Ratio

ENTAN/A

SRZNN/A

EV/FCF

ENTA-12.36x

SRZN-6.94x

PEG Ratio

ENTAN/A

SRZNN/A

Forward P/E (NTM)

ENTAN/A

SRZNN/A

Forward P/S (NTM)

ENTA6.51x

SRZN118.58x

Revenue (TTM)

ENTA$65M

SRZN$12M

Revenue Growth (YoY)

ENTA0.7%

SRZN-8.8%

Forward Rev Growth

ENTA-7.3%

SRZN-82.6%

Gross Margin (TTM)

ENTA0.0%

SRZN0.0%

Operating Margin (TTM)

ENTA0.0%

SRZN0.0%

EBITDA Margin (TTM)

ENTA-82.5%

SRZN-383.4%

Net Margin (TTM)

ENTA-96.9%

SRZN-2885.3%

FCF Margin (TTM)

ENTA-56.6%

SRZN-303.9%

Net Income (TTM)

ENTA$-63M

SRZN$-332M

FCF (TTM)

ENTA$-37M

SRZN$-35M

EPS (TTM)

ENTA-$2.17

SRZN-$28.48

ROE (TTM)

ENTA-6184.0%

SRZN58.2%

ROA (TTM)

ENTA-2070.0%

SRZN-30962.0%

ROIC (TTM)

ENTA-2677.0%

SRZN58.2%

Cash

ENTA$33M

SRZN$102M

Debt

ENTA$126M

SRZN$0

Net Cash/Debt

ENTA$-93M

SRZN$102M

Current Ratio (TTM)

ENTA3.76x

SRZN12.14x

Quick Ratio (TTM)

ENTA3.62x

SRZN11.88x

Debt/Equity (TTM)

ENTA1.25x

SRZN0.00x

Debt/Assets (TTM)

ENTA0.0%

SRZN0.0%

Interest Coverage (TTM)

ENTAN/A

SRZNN/A

Net Debt/EBITDA (TTM)

ENTA0.00x

SRZN0.00x

Beta

ENTA0.72

SRZN0.53

52W Performance

ENTA10.6%

SRZN111.5%

YTD Performance

ENTA-13.3%

SRZN37.8%

% from 52W High

ENTA-27.1%

SRZN-21.5%

% from 52W Low

ENTA22.5%

SRZN160.7%

Asset Turnover (TTM)

ENTA0.21x

SRZN0.11x

FCF Yield (TTM)

ENTA-10.2%

SRZN-10.1%

Earnings Yield (TTM)

ENTA-17.4%

SRZN-96.4%

Dividend Yield (TTM)

ENTAN/A

SRZNN/A

Rule of 40

ENTA-55.9

SRZN-312.7

EV/GP/RG

ENTAN/A

SRZNN/A

Ticker research

View ENTA research View SRZN research

Metric	ENTA Enanta Pharmaceuticals Inc	SRZN Surrozen Inc
Market & Valuation
Market Cap	$364M	$345M
Enterprise Value	$456M	$243M
Price	$12.50	$29.69
P/E Ratio	N/A	N/A
P/S Ratio	5.57x	29.95x
EV/Sales	6.99x	21.08x
EV/EBITDA	31.83x	0.00x
P/B Ratio	3.73x	7.31x
P/FCF Ratio	N/A	N/A
EV/FCF	-12.36x	-6.94x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	6.51x	118.58x
Revenue & Growth
Revenue (TTM)	$65M	$12M
Revenue Growth (YoY)	0.7%	-8.8%
Forward Rev Growth	-7.3%	-82.6%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-82.5%	-383.4%
Net Margin (TTM)	-96.9%	-2885.3%
FCF Margin (TTM)	-56.6%	-303.9%
Net Income (TTM)	$-63M	$-332M
FCF (TTM)	$-37M	$-35M
EPS (TTM)	-$2.17	-$28.48
ROE (TTM)	-6184.0%	58.2%
ROA (TTM)	-2070.0%	-30962.0%
ROIC (TTM)	-2677.0%	58.2%
Financial Health
Cash	$33M	$102M
Debt	$126M	$0
Net Cash/Debt	$-93M	$102M
Current Ratio (TTM)	3.76x	12.14x
Quick Ratio (TTM)	3.62x	11.88x
Debt/Equity (TTM)	1.25x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.72	0.53
52W Performance	10.6%	111.5%
YTD Performance	-13.3%	37.8%
% from 52W High	-27.1%	-21.5%
% from 52W Low	22.5%	160.7%
Efficiency & Yields
Asset Turnover (TTM)	0.21x	0.11x
FCF Yield (TTM)	-10.2%	-10.1%
Earnings Yield (TTM)	-17.4%	-96.4%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-55.9	-312.7
EV/GP/RG	N/A	N/A
Ticker research	View ENTA research	View SRZN research

Valuation

P/S Ratio

ENTA

5.57x

SRZN

29.95x

EV/FCF

ENTA

-12.36x

SRZN

-6.94x

Growth & revenue

Revenue Growth TTM

ENTA

0.7%

SRZN

-8.8%

Forward Revenue Growth

ENTA

-7.3%

SRZN

-82.6%

Profitability & performance

Gross Margin

ENTA

0.0%

SRZN

0.0%

ROE

SRZN

58.2%

ENTA

-6184.0%

FCF Yield %

SRZN

-10.1%

ENTA

-10.2%

52-Week Performance

SRZN

111.5%

ENTA

10.6%

Detailed metrics comparison

ENTA

Enanta Pharmaceuticals Inc

SRZN

Surrozen Inc

Market Cap

ENTA$364M

SRZN$345M

Enterprise Value

ENTA$456M

SRZN$243M

Price

ENTA$12.50

SRZN$29.69

P/E Ratio

ENTAN/A

SRZNN/A

P/S Ratio

ENTA5.57x

SRZN29.95x

EV/Sales

ENTA6.99x

SRZN21.08x

EV/EBITDA

ENTA31.83x

SRZN0.00x

P/B Ratio

ENTA3.73x

SRZN7.31x

P/FCF Ratio

ENTAN/A

SRZNN/A

EV/FCF

ENTA-12.36x

SRZN-6.94x

PEG Ratio

ENTAN/A

SRZNN/A

Forward P/E (NTM)

ENTAN/A

SRZNN/A

Forward P/S (NTM)

ENTA6.51x

SRZN118.58x

Revenue (TTM)

ENTA$65M

SRZN$12M

Revenue Growth (YoY)

ENTA0.7%

SRZN-8.8%

Forward Rev Growth

ENTA-7.3%

SRZN-82.6%

Gross Margin (TTM)

ENTA0.0%

SRZN0.0%

Operating Margin (TTM)

ENTA0.0%

SRZN0.0%

EBITDA Margin (TTM)

ENTA-82.5%

SRZN-383.4%

Net Margin (TTM)

ENTA-96.9%

SRZN-2885.3%

FCF Margin (TTM)

ENTA-56.6%

SRZN-303.9%

Net Income (TTM)

ENTA$-63M

SRZN$-332M

FCF (TTM)

ENTA$-37M

SRZN$-35M

EPS (TTM)

ENTA-$2.17

SRZN-$28.48

ROE (TTM)

ENTA-6184.0%

SRZN58.2%

ROA (TTM)

ENTA-2070.0%

SRZN-30962.0%

ROIC (TTM)

ENTA-2677.0%

SRZN58.2%

Cash

ENTA$33M

SRZN$102M

Debt

ENTA$126M

SRZN$0

Net Cash/Debt

ENTA$-93M

SRZN$102M

Current Ratio (TTM)

ENTA3.76x

SRZN12.14x

Quick Ratio (TTM)

ENTA3.62x

SRZN11.88x

Debt/Equity (TTM)

ENTA1.25x

SRZN0.00x

Debt/Assets (TTM)

ENTA0.0%

SRZN0.0%

Interest Coverage (TTM)

ENTAN/A

SRZNN/A

Net Debt/EBITDA (TTM)

ENTA0.00x

SRZN0.00x

Beta

ENTA0.72

SRZN0.53

52W Performance

ENTA10.6%

SRZN111.5%

YTD Performance

ENTA-13.3%

SRZN37.8%

% from 52W High

ENTA-27.1%

SRZN-21.5%

% from 52W Low

ENTA22.5%

SRZN160.7%

Asset Turnover (TTM)

ENTA0.21x

SRZN0.11x

FCF Yield (TTM)

ENTA-10.2%

SRZN-10.1%

Earnings Yield (TTM)

ENTA-17.4%

SRZN-96.4%

Dividend Yield (TTM)

ENTAN/A

SRZNN/A

Rule of 40

ENTA-55.9

SRZN-312.7

EV/GP/RG

ENTAN/A

SRZNN/A

Ticker research

View ENTA research View SRZN research

Metric	ENTA Enanta Pharmaceuticals Inc	SRZN Surrozen Inc
Market & Valuation
Market Cap	$364M	$345M
Enterprise Value	$456M	$243M
Price	$12.50	$29.69
P/E Ratio	N/A	N/A
P/S Ratio	5.57x	29.95x
EV/Sales	6.99x	21.08x
EV/EBITDA	31.83x	0.00x
P/B Ratio	3.73x	7.31x
P/FCF Ratio	N/A	N/A
EV/FCF	-12.36x	-6.94x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	6.51x	118.58x
Revenue & Growth
Revenue (TTM)	$65M	$12M
Revenue Growth (YoY)	0.7%	-8.8%
Forward Rev Growth	-7.3%	-82.6%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-82.5%	-383.4%
Net Margin (TTM)	-96.9%	-2885.3%
FCF Margin (TTM)	-56.6%	-303.9%
Net Income (TTM)	$-63M	$-332M
FCF (TTM)	$-37M	$-35M
EPS (TTM)	-$2.17	-$28.48
ROE (TTM)	-6184.0%	58.2%
ROA (TTM)	-2070.0%	-30962.0%
ROIC (TTM)	-2677.0%	58.2%
Financial Health
Cash	$33M	$102M
Debt	$126M	$0
Net Cash/Debt	$-93M	$102M
Current Ratio (TTM)	3.76x	12.14x
Quick Ratio (TTM)	3.62x	11.88x
Debt/Equity (TTM)	1.25x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.72	0.53
52W Performance	10.6%	111.5%
YTD Performance	-13.3%	37.8%
% from 52W High	-27.1%	-21.5%
% from 52W Low	22.5%	160.7%
Efficiency & Yields
Asset Turnover (TTM)	0.21x	0.11x
FCF Yield (TTM)	-10.2%	-10.1%
Earnings Yield (TTM)	-17.4%	-96.4%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-55.9	-312.7
EV/GP/RG	N/A	N/A
Ticker research	View ENTA research	View SRZN research